Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel S Childs

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Clinical and Translational Radiation Oncology|April 24, 2026
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancerAndres L Frias, Bradley J Stish, Ryan M Phillips, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Clinical Genitourinary Cancer|April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Ronit Juthani, Oliver Sartor, et al.
European Urology|January 23, 2025
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysisSyed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2024
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patientsSurendra Dasari, Michael R McCarthy, Antonina A Wojcik, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewSyed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, et al.
European Urology|November 5, 2025
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Cancer Treatment Reviews|May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are goingMiguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Clinical and Translational Radiation Oncology|April 24, 2026
Outcomes of stereotactic body radiotherapy for supraclavicular lymph node metastasis among patients with metastatic prostate cancerAndres L Frias, Bradley J Stish, Ryan M Phillips, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Clinical Genitourinary Cancer|April 17, 2026
LuRa: Efficacy and Safety of Radium-223 Following [<sup>177</sup>Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerJabra Zarka, Ronit Juthani, Oliver Sartor, et al.
European Urology|January 23, 2025
Heterogeneity of the Treatment Effect with PARP Inhibitors in Metastatic Castration-resistant Prostate Cancer: A Living Interactive Systematic Review and Meta-analysisSyed Arsalan Ahmed Naqvi, Irbaz Bin Riaz, Arifa Bibi, et al.
Prostate Cancer and Prostatic Diseases|February 27, 2024
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patientsSurendra Dasari, Michael R McCarthy, Antonina A Wojcik, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewSyed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, et al.
European Urology|November 5, 2025
Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysisIrbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, Kunwer Sufyan Faisal, et al.
Nature Communications|March 14, 2025
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trialJacob J Orme, Henan Zhang, Prashanth Lingamaneni, et al.
European Urology Oncology|December 10, 2023
Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate CancerJacob J Orme, Fadi Taza, Navonil De Sarkar, et al.
Pageof 6